argenx SE reported $321.35M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AstraZeneca USD 5.01B 1.42B Jun/2025
Galapagos EUR 30.67M 13.12M Jun/2025
Genmab DKK 144M 18M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
GRIFOLS EUR 282.76M 41.9M Jun/2025
Hikma Pharmaceutical USD 288M 8M Dec/2024
Qiagen NV USD 148.74M 10.8M Jun/2025
UCB EUR 1.29B 221M Dec/2024